Atypical chronic myeloid leukemia (aCML) is an aggressive myeloid neoplasm with overlapping features of myelodysplastic syndromes (prominent granulocytic dysplasia) and myeloproliferative neoplasms (neutrophilic leukocytosis). We studied 25 molecularly-annotated and World Health Organization defined aCML patients; median age 70 years, 84% males. Cytogenetic abnormalities were seen in 36% and gene mutations in 100%. Mutational frequencies were, ASXL1 28%, TET2 16%, NRAS 16%, SETBP1 12%, RUNX1 12%, ETNK1 8%, and PTPN11 4%. Fifteen patients (60%) had >1 mutation, while 9 (36%) had 3. The median overall survival (OS) was 10.8 months and at last follow up (median 11 months), 17 (68%) deaths and 2 (8%) leukemic transformations were documented. On univariate analysis, survival was adversely impacted by advanced age (P 5 .02), low hemoglobin (P 5 .01), red blood cell transfusion dependence (P 5 .03), high white blood cell count (P 5 .02), TET2 (P 5 .03), NRAS (P 5 .04), PTPN11 (P 5 .02) mutations and the presence of 3 gene mutations (P 5 .006); ASXL1, SETBP1, and ETNK1 mutations did not impact OS. In multivariable analysis, advanced age (P 5 .003) [age >67: HR 10.1, 95% CI 1.3-119], low hemoglobin (P 5 .008) [HB< 10 gm/dL: HR 8.2, 95% CI 1.6-23.2] and TET2 mutations (P 5 .01) [HR 8.8,] retained prognostic significance. We then used age >67 years, hemoglobin <10 gm/dL and the presence of TET2 mutations (each counted as one risk factor) to create a hazard ratio weighted prognostic model; effectively stratifying patients into two risk categories, low (0-1 risk factor) and high (2 risk factors), with median OS of 18 and 7 months, respectively.
| I N T R O D U C T I O N
Atypical chronic myeloid leukemia (aCML) is a BCR-ABL1 negative, clonal, hematopoietic stem cell disorder, with overlapping features of myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN). 1 Atypical CML is a rare disease, with an estimated frequency of 1 to 2 cases for every 100 patients with BCR-ABL1 rearranged CML. clumping, (3) no or minimal absolute basophilia (<2% of leukocytes), (4) no or minimal absolute monocytosis (<10% of leukocytes), (5) hypercellular bone marrow (BM) with granulocytic proliferation and granulocytic dysplasia, with or without dysplasia in the erythroid or megakaryocytic lineages, (6) <20% blasts in the PB and BM, and (7) not meeting diagnostic criteria for BCR-ABL1 rearranged CML, primary myelofibrosis (PMF), polycythemia vera (PV), or essential thrombocythemia (ET). 1, 3 In addition, great caution is suggested while making a diagnosis of aCML in a patient with a previous history of MPN, or in the presence of MPN like features in the BM, or in the presence of MPN-associated driver mutations such as JAK2, CALR, and MPL. The median overall survival (OS) in patients with aCML is 25 months (range, 14-30 months), with high leukemic transformation rates (40%, within 18 months of diagnosis). 2, 4, 5 Reported prognostic factors impacting survival include; age >65 years, female gender, leukocyte count >50 3 10(9)/L, hemoglobin <10 gm/dL and the presence of circulating immature myeloid cells (IMC). 2, 5 Next-generation sequencing (NGS) technology has identified recurrent mutations involving ASXL1, TET2, SETBP1, ETNK1, NRAS, EZH2, and U2AF1 among others, in affected patients. [6] [7] [8] SETBP1 mutations are seen in 25% of patients and are associated with leukocytosis and a shorter OS. 6,7 TET2
(40%) and ETNK1 (8%) mutations have also been reported in aCML, with an indeterminate prognostic impact. 6, 8 We performed this study to (1) identify prognostically-relevant mutations in aCML, (2) determine the prognostic impact of the number of concurrent mutations; and (3) identify clinical and laboratory parameters impacting OS and leukemiafree survival (LFS).
| MATERIALS A ND METHODS
Twenty-five patients with atypical CML were included in the study. All patients had BM biopsies and cytogenetic studies performed at diagno- TET2, DNMT3A, IDH1, IDH2, ASXL1,   EZH2, SUZ12, SRSF2, SF3B1, ZRSR2, U2AF1, PTPN11, Tp53, SH2B3,   RUNX1, CBL, NRAS, KRAS, JAK2, CSF3R, FLT3, KIT, CALR, MPL, NPM1, CEBPA, IKZF, ETNK1, and SETBP1. 
| R E S U L T S
Twenty-five patients with WHO defined atypical CML, with a median age of 70 years (range, 49-91), 84% males, seen at the Mayo Clinic from 1990-2015, were included in this study. Table 1 lists the clinical and laboratory details and subsequent events in these patients, stratified by their TET2 mutational status. At a median follow up of 11 months (range, 1-29), 17 (68%) deaths and 2 (8%) leukemic transformations were documented. Five (62%) of 8 patients alive were lost to follow up after a median of 7 months (range, 0-13), while 3 patients are being actively followed with a median follow up of 12 months (range, 6-13). All patients had BM dysgranulopoiesis, whereas dyserythropoiesis and dysmegakaryopoiesis were present in 16% (4/25) and 20%
(5/25), respectively. Of 22 evaluable patients, BM reticulin fibrosis (WHO grades1-2 of 3) was seen in 14 (67%). Sixteen (64%) patients were red blood cell transfusion dependent at diagnosis, and 11(44%) had palpable splenomegaly, of which, 3 (12%) had massive splenomegaly (spleen size palpable >10 cm below the left costal margin). ); while there were one (5%) each, with trisomy 9 and trisomy 21, respectively. All patients tested negative for BCR-ABL1 by conventional metaphase cytogenetics and/or fluorescence in situ hybridization techniques. There was no statistically significant difference in the occurrence of cytogenetic abnormalities in the TET2 mutated and wild type aCML patients (P 5 .6).
Mutational frequencies were 28% (7/25) for ASXL1, 16% (4/25) for TET2 and NRAS, 12% (3/25) for SETBP1, RUNX1, and SRSF2, 8% (2/25) for ETNK1, SF3B1, KRAS, EZH2, CSF3R, and JAK2V617F, and 4%
(1/25) for IDH2, ZRSR2, PTPN11, and FLT3-TKD, respectively. No There were 2 patients with ETNK1 mutations, both of whom demonstrated the c.731A > G; p.N244S change. Both these patients had normal absolute eosinophil counts. There were two (8%) patients with the JAK2V617F mutation, with WHO grade 1 BM fibrosis, in whom a diagnosis of PMF was excluded. There were two (8%) patients with CSF3R
mutations, both demonstrating the c.1853C > T T618I change. These patients had both, marked neutrophilia (absolute neutrophil count
[ANC] > 50 3 10(9)/L) and marked granulocytic dysplasia, meeting WHO criteria for a diagnosis of aCML. BM ring sideroblasts were not detected in the 2 SF3B1 mutated patients with aCML. TET2 mutated aCML patients were more likely to have concurrent mutations involving SH2B3, NRAS, and PTPN11, in comparison to their wild type counterparts (Table 1) .
Treatment data was available on all 25 patients. Fifteen (60%) patients received hydroxyurea for the management of progressive myeloproliferation, while 4 (16%) received erythropoiesis stimulating agents (ESA) for anemia. One patient each received interferon alpha, thalidomide and lenalidomide as disease modifying agents. In all three cases, the respective agents were discontinued due to poor response and poor tolerability. Five (25%) patients were treated with hypomethylating agents (HMA) for refractory anemia and concomitant myeloproliferation; 4 (16%) with 5-azacitidine and 1 (4%) with decitabine. 5-Azacitidine was administered for a mean of 5 cycles (range, 1-10), with the best response being stable disease (40%), while one patient received 2 cycles of decitabine and had to discontinue the same due to progressive neutrophilia. No patients underwent allogeneic stem cell transplantation. Cause of death was known in 7 (41%) patients and included 2 (28%) deaths secondary to complications from leukemic transformation, 3 (43%) from complications related to sepsis and one each (14%) from subarachnoid hemorrhage and intracerebral hemorrhage, respectively. The remaining deaths occurred outside our institution and were attributed to the patients underlying disease; however the exact cause of death could not be ascertained.
| Predictors of over-all survival
The median OS for the cohort was 10.8 months. In an univariate OS comprising <10% of leukocytes and CMML, a MDS/MPN overlap syndrome characterized by absolute monocytosis (PB AMC >1 3 10(9)/L for >3 months) and BM dysplasia. 13 In concordance with prior studies, the median age at presentation in our study was 70 years, with a male preponderance (84%). BM dysgranulopoiesis was seen in all (100%) patients, while dyserythropoiesis and dysmegakaryopoiesis were Next-generation sequencing analysis; n (%)
Epigenetic regulators
2. Chromatin regulation
4. Spliceosome components
5. Cell signaling and point mutations in the extracellular domain of CSF3R (membrane proximal mutations); with the membrane proximal T618I mutation being the most common. 18 These mutations are uncommon in aCML and in our prior study were documented in 83% of patients with CNL (n 5 12) and 0% of aCML (n 5 9) patients. 19 In our current series of 25 aCML patients, we identified CSF3RT618I mutations in 2 (8%) patients, with variant allele frequency burdens of 33% and 48%, respectively. 
